Neuromyelitis Optica Spectrum Disorder Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Hoffmann-La Roche Ltd, Horizon

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Neuromyelitis Optica Spectrum Disorder pipeline constitutes 15+ key companies continuously working towards developing 15+ Neuromyelitis Optica Spectrum Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Neuromyelitis Optica Spectrum Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Neuromyelitis Optica Spectrum Disorder Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuromyelitis Optica Spectrum Disorder Market.

Some of the key takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report:

* Companies across the globe are diligently working toward developing novel Neuromyelitis Optica Spectrum Disorder treatment therapies with a considerable amount of success over the years.
* Neuromyelitis Optica Spectrum Disorder companies working in the treatment market are Harbour BioMed, Reistone Biopharma, RemeGen, ENDECE, Aeterna Zentaris, Shanghai Pharmaceuticals Holding Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., Alexion Pharmaceuticals, and others , are developing therapies for the Neuromyelitis Optica Spectrum Disorder treatment
* Emerging Neuromyelitis Optica Spectrum Disorder therapies in the different phases of clinical trials are- HBM9161, SHR1459, Telitacicept, NDC-1308, AIM Biologicals, B001, LP-168, Ravulizumab, and others are expected to have a significant impact on the Neuromyelitis Optica Spectrum Disorder market in the coming years.
* In March 2024, Alexion Pharmaceuticals Ultomiris gained FDA approval for treating adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. The decision stemmed from encouraging outcomes in the phase 3 CHAMPION-NMOSD trial, comparing Ultomiris (ravulizumab-cwvz), a prolonged-acting C5 complement inhibitor, with a placebo arm from the pivotal Soliris (eculizumab) PREVENT clinical trial.
* In June 2022, Alexion Pharmaceuticals commenced a Phase II/III clinical trial, employing an open-label, historical-controlled, single-arm, multicenter approach to assess the effectiveness, pharmacokinetics, pharmacodynamics, and safety of ravulizumab in children and adolescents diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) who test positive for aquaporin-4 antibodies (AQP4-Ab [+]).
* In June 2022, The Brazilian Health Regulatory Agency (ANVISA) granted approval for UPLIZNA as a standalone treatment intended for adult patients diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) who exhibit a positive test result for the AQP4-IgG biomarker.
* In May 2022, The European Commission granted approval to UPLIZNA, a medication created by Horizon Therapeutics, as a standalone treatment for adult individuals diagnosed with neuromyelitis optica spectrum disorder (NMOSD). This approval encompasses all adult NMOSD patients, irrespective of their AQP4-IgG biomarker test results.

Neuromyelitis Optica Spectrum Disorder Overview

Neuromyelitis Optica Spectrum Disorder (NMOSD), also recognized as Devic disease, is a persistent condition affecting the brain and spinal cord, primarily characterized by inflammation in the optic nerve (optic neuritis) and the spinal cord (myelitis). The occurrence and frequency of NMOSD vary, with reported rates ranging from 0.05-0.40 and 0.52-4.4 per 100,000 individuals, respectively.

Get a Free Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight [https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Neuromyelitis Optica Spectrum Disorder Drugs Under Different Phases of Clinical Development Include:

* HBM9161: Harbour BioMed
* SHR1459: Reistone Biopharma
* Telitacicept: RemeGen
* NDC-1308: ENDECE
* AIM Biologicals: Aeterna Zentaris
* B001: Shanghai Pharmaceuticals Holding Co., Ltd.
* LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
* Ravulizumab: Alexion Pharmaceuticals

Neuromyelitis Optica Spectrum Disorder Route of Administration

Neuromyelitis Optica Spectrum Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Intravenous
* Oral
* Subcutaneous
* Molecule Type

Neuromyelitis Optica Spectrum Disorder Molecule Type

Neuromyelitis Optica Spectrum Disorder Products have been categorized under various Molecule types, such as

* Immunoglobulin
* Monoclonal antibodies
* Protein
* Recombinant fusion proteins
* Small molecules
* Vaccine
* Product Type

Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics Assessment

* Neuromyelitis Optica Spectrum Disorder Assessment by Product Type
* Neuromyelitis Optica Spectrum Disorder By Stage and Product Type
* Neuromyelitis Optica Spectrum Disorder Assessment by Route of Administration
* Neuromyelitis Optica Spectrum Disorder By Stage and Route of Administration
* Neuromyelitis Optica Spectrum Disorder Assessment by Molecule Type
* Neuromyelitis Optica Spectrum Disorder by Stage and Molecule Type

DelveInsight's Neuromyelitis Optica Spectrum Disorder Report covers around 15+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Further Neuromyelitis Optica Spectrum Disorder product details are provided in the report. Download the Neuromyelitis Optica Spectrum Disorder pipeline report to learn more about the emerging Neuromyelitis Optica Spectrum Disorder therapies [https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Neuromyelitis Optica Spectrum Disorder Therapeutics Market include:

Key companies developing therapies for Neuromyelitis Optica Spectrum Disorder are - Hoffmann-La Roche Ltd, Horizon Therapeutics plc, TG Therapeutics, Opexa Therapeutics, Mitsubishi Tanabe Pharma, Remegen, Teva Pharma, TG Therapeutics, Astrazeneca, Harbour Biomed, and others.

Neuromyelitis Optica Spectrum Disorder Pipeline Analysis:

The Neuromyelitis Optica Spectrum Disorder pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Neuromyelitis Optica Spectrum Disorder with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuromyelitis Optica Spectrum Disorder Treatment.
* Neuromyelitis Optica Spectrum Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Neuromyelitis Optica Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuromyelitis Optica Spectrum Disorder market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder drugs and therapies [https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Neuromyelitis Optica Spectrum Disorder Pipeline Market Drivers

* Increase in NMOSD prevalence, rising awareness among general population about NMOSD, emergence of novel therapies are some of the important factors that are fueling the Neuromyelitis Optica Spectrum Disorder Market.

Neuromyelitis Optica Spectrum Disorder Pipeline Market Barriers

* However, dearth of skilled professionals and lack of healthcare infrastructure in developing economies, high costs for NMOSD treatment and other factors are creating obstacles in the Neuromyelitis Optica Spectrum Disorder Market growth.

Scope of Neuromyelitis Optica Spectrum Disorder Pipeline Drug Insight

* Coverage: Global
* Key Neuromyelitis Optica Spectrum Disorder Companies: Harbour BioMed, Reistone Biopharma, RemeGen, ENDECE, Aeterna Zentaris, Shanghai Pharmaceuticals Holding Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., Alexion Pharmaceuticals, and others
* Key Neuromyelitis Optica Spectrum Disorder Therapies: HBM9161, SHR1459, Telitacicept, NDC-1308, AIM Biologicals, B001, LP-168, Ravulizumab, and others
* Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment: Neuromyelitis Optica Spectrum Disorder current marketed and Neuromyelitis Optica Spectrum Disorder emerging therapies
* Neuromyelitis Optica Spectrum Disorder Market Dynamics: Neuromyelitis Optica Spectrum Disorder market drivers and Neuromyelitis Optica Spectrum Disorder market barriers

Request for Sample PDF Report for Neuromyelitis Optica Spectrum Disorder Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Neuromyelitis Optica Spectrum Disorder Report Introduction

2. Neuromyelitis Optica Spectrum Disorder Executive Summary

3. Neuromyelitis Optica Spectrum Disorder Overview

4. Neuromyelitis Optica Spectrum Disorder- Analytical Perspective In-depth Commercial Assessment

5. Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics

6. Neuromyelitis Optica Spectrum Disorder Late Stage Products (Phase II/III)

7. Neuromyelitis Optica Spectrum Disorder Mid Stage Products (Phase II)

8. Neuromyelitis Optica Spectrum Disorder Early Stage Products (Phase I)

9. Neuromyelitis Optica Spectrum Disorder Preclinical Stage Products

10. Neuromyelitis Optica Spectrum Disorder Therapeutics Assessment

11. Neuromyelitis Optica Spectrum Disorder Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neuromyelitis Optica Spectrum Disorder Key Companies

14. Neuromyelitis Optica Spectrum Disorder Key Products

15. Neuromyelitis Optica Spectrum Disorder Unmet Needs

16 . Neuromyelitis Optica Spectrum Disorder Market Drivers and Barriers

17. Neuromyelitis Optica Spectrum Disorder Future Perspectives and Conclusion

18. Neuromyelitis Optica Spectrum Disorder Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuromyelitis-optica-spectrum-disorder-pipeline-and-clinical-trials-assessment-2024-updates-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-hoffmannla-roche-ltd-horizon]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.